Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-mediated Uptake.

Morse BL, Kolur A, Hudson LR, Hogan AT, Chen LH, Brackman RM, Sawada GA, Fallon JK, Smith PC, Hillgren KM.

Drug Metab Dispos. 2019 Nov 26. pii: dmd.119.088781. doi: 10.1124/dmd.119.088781. [Epub ahead of print]

2.

Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion.

Morse BL, Alberts JJ, Posada MM, Rehmel J, Kolur A, Tham LS, Loghin C, Hillgren KM, Hall SD, Dickinson GL.

CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):664-675. doi: 10.1002/psp4.12447. Epub 2019 Aug 1.

3.

Hepatic Organic Anion Transporting Polypeptide-Mediated Clearance in the Beagle Dog: Assessing In Vitro-In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance.

Matsunaga N, Ufuk A, Morse BL, Bedwell DW, Bao J, Mohutsky MA, Hillgren KM, Hall SD, Houston JB, Galetin A.

Drug Metab Dispos. 2019 Mar;47(3):215-226. doi: 10.1124/dmd.118.084194. Epub 2018 Dec 28.

PMID:
30593544
4.

The Drug of Abuse Gamma-Hydroxybutyric Acid Exhibits Tissue-Specific Nonlinear Distribution.

Felmlee MA, Morse BL, Follman KE, Morris ME.

AAPS J. 2017 Dec 26;20(1):21. doi: 10.1208/s12248-017-0180-7.

5.

Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol.

McLean CC, Teft WA, Morse BL, Gryn SE, Hegele RA, Kim RB.

Clin Pharmacol Ther. 2018 Sep;104(3):525-533. doi: 10.1002/cpt.973. Epub 2018 Jan 8.

PMID:
29218707
6.

Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys.

Morse BL, MacGuire JG, Marino AM, Zhao Y, Fox M, Zhang Y, Shen H, Griffith Humphreys W, Marathe P, Lai Y.

AAPS J. 2017 Nov;19(6):1878-1889. doi: 10.1208/s12248-017-0151-z. Epub 2017 Oct 10.

PMID:
29019117
7.

Effect of chronic γ-hydroxybutyrate (GHB) administration on GHB toxicokinetics and GHB-induced respiratory depression.

Morse BL, Chadha GS, Felmlee MA, Follman KE, Morris ME.

Am J Drug Alcohol Abuse. 2017 Nov;43(6):686-693. doi: 10.1080/00952990.2017.1339055. Epub 2017 Jun 29.

8.

Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters.

Teft WA, Morse BL, Leake BF, Wilson A, Mansell SE, Hegele RA, Ho RH, Kim RB.

Mol Pharm. 2017 Jan 3;14(1):310-318. doi: 10.1021/acs.molpharmaceut.6b00937. Epub 2016 Dec 15.

9.

Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events.

Kim RB, Morse BL, Djurdjev O, Tang M, Muirhead N, Barrett B, Holmes DT, Madore F, Clase CM, Rigatto C, Levin A; CanPREDDICT Investigators.

Kidney Int. 2016 May;89(5):1144-1152. doi: 10.1016/j.kint.2016.01.014. Epub 2016 Mar 19.

PMID:
27083288
10.

Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake.

Morse BL, Cai H, MacGuire JG, Fox M, Zhang L, Zhang Y, Gu X, Shen H, Dierks EA, Su H, Luk CE, Marathe P, Shu YZ, Humphreys WG, Lai Y.

Drug Metab Dispos. 2015 Nov;43(11):1788-94. doi: 10.1124/dmd.115.065946. Epub 2015 Sep 4.

PMID:
26341276
11.

Erratum to: Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease.

Wilson A, Teft WA, Morse BL, Choi YH, Woolsey S, DeGorter MK, Hegele RA, Tirona RG, Kim RB.

Dig Dis Sci. 2016 Jan;61(1):325. doi: 10.1007/s10620-015-3826-2. No abstract available.

PMID:
26233551
12.

Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease.

Wilson A, Teft WA, Morse BL, Choi YH, Woolsey S, DeGorter MK, Hegele RA, Tirona RG, Kim RB.

Dig Dis Sci. 2015 Dec;60(12):3620-30. doi: 10.1007/s10620-015-3797-3. Epub 2015 Jul 10. Erratum in: Dig Dis Sci. 2016 Jan;61(1):325.

PMID:
26160437
13.

Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression.

Shen H, Liu T, Morse BL, Zhao Y, Zhang Y, Qiu X, Chen C, Lewin AC, Wang XT, Liu G, Christopher LJ, Marathe P, Lai Y.

Drug Metab Dispos. 2015 Jul;43(7):984-93. doi: 10.1124/dmd.114.062364. Epub 2015 Apr 22.

PMID:
25904762
14.

A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose.

Vijay N, Morse BL, Morris ME.

Pharm Res. 2015 Jun;32(6):1894-906. doi: 10.1007/s11095-014-1583-0. Epub 2014 Dec 6.

15.

Is personalized medicine a dream or a reality?

Morse BL, Kim RB.

Crit Rev Clin Lab Sci. 2015 Feb;52(1):1-11. doi: 10.3109/10408363.2014.950407. Epub 2014 Sep 2.

PMID:
25181036
16.

Mechanistic modeling of monocarboxylate transporter-mediated toxicokinetic/toxicodynamic interactions between γ-hydroxybutyrate and L-lactate.

Morse BL, Vijay N, Morris ME.

AAPS J. 2014 Jul;16(4):756-70. doi: 10.1208/s12248-014-9593-8. Epub 2014 May 23.

17.

Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate-ethanol intoxication: evaluation of potential treatment strategies.

Morse BL, Morris ME.

J Pharmacol Exp Ther. 2013 Sep;346(3):504-13. doi: 10.1124/jpet.113.206250. Epub 2013 Jun 28.

18.

Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone.

Morse BL, Morris ME.

J Pharmacol Exp Ther. 2013 Apr;345(1):102-10. doi: 10.1124/jpet.112.202796. Epub 2013 Feb 7.

19.

γ-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose.

Morse BL, Vijay N, Morris ME.

Mol Pharmacol. 2012 Aug;82(2):226-35. doi: 10.1124/mol.112.078154. Epub 2012 May 4.

20.

Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study.

Morris ME, Morse BL, Baciewicz GJ, Tessena MM, Acquisto NM, Hutchinson DJ, Dicenzo R.

J Clin Toxicol. 2011 Nov 10;1(2):1000105.

21.

γ-Hydroxybutyrate blood/plasma partitioning: effect of physiologic pH on transport by monocarboxylate transporters.

Morse BL, Felmlee MA, Morris ME.

Drug Metab Dispos. 2012 Jan;40(1):64-9. doi: 10.1124/dmd.111.041285. Epub 2011 Oct 5.

22.

Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid.

Felmlee MA, Krzyzanski W, Morse BL, Morris ME.

AAPS J. 2011 Jun;13(2):240-54. doi: 10.1208/s12248-011-9264-y. Epub 2011 Mar 9.

23.

Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acid.

Felmlee MA, Roiko SA, Morse BL, Morris ME.

J Pharmacol Exp Ther. 2010 Jun;333(3):764-71. doi: 10.1124/jpet.109.165381. Epub 2010 Mar 9.

Supplemental Content

Loading ...
Support Center